Notice type: 3rd Party Publications
Problem Or Issue:
Important information from Eli Lilly and Company Ltd.: Revocation of the EU marketing authorisation for Lartruvo (olaratumab) due to lack of therapeutic efficacy.
Important Information - Lartruvo (olaratumab)